Efficacy and safety of garenoxacin in the treatment of upperrespiratory tract infections.
Efficacy and safety of garenoxacin in the treatment of upperrespiratory tract infections.
复制标题
加雷诺沙星治疗上呼吸道感染的疗效和安全性。
DOI：
10.1016/j.anl.2011.09.004
复制
发表时间：
2012
影响因子：
1.7
通讯作者：
Yoshizaki T
中科院分区：
文献类型：
--
作者：
Ito M;Maruyama Y;Murono S;Wakisaka N;Kondo S;Hatano M;Nakanishi S;MiwaT;Yoshizaki T
目的观察新一代喹诺酮类抗菌药物阿诺沙星治疗成人上呼吸道感染的疗效和安全性。咽喉炎、扁桃体炎和中耳炎患者服用加诺沙星（400 mg/天）5-7天，鼻窦炎患者服用7-10天。临床症状和结果进行了检查和定量评估使用scoringsystems. CITTS我们发现80至100%的改善率的症状和结果的每一个感染。此外，我们发现即使在治疗的早期阶段，患者问卷的主观评价也有显着改善。急性鼻窦炎X线检查显示临床疗效为84%（27/32），76%（19/25）的患者在7天内好转。在检出的84株细菌中，75株（89%）被鉴定为呼吸道感染的主要病原菌，如猪链球菌（27株）和流感嗜血杆菌（14株）。加诺沙星给药完全根除了54例中的53例（98%）。不良反应8例（8.3%），其中腹泻3例（3.1%）。结论：诺氟沙星治疗社区获得性上呼吸道感染是一种高效、安全的抗菌药物。此外，由于其强大的抗菌活性，阿伐诺沙星不会诱导耐药菌的生长。
OBJECTIVETo determine the efficacy and safety of garenoxacin, a new generation of quinolone antimicrobial agent, in the treatment of adult upper respiratory tract infections.METHODSA total of 113 subjects were enrolled in this study. Garenoxacin (400mg/day) was administered to patients with pharyngolaryngitis, tonsillitis, and otitis media for 5–7 days and to those with sinusitis for 7–10 days. Clinical symptoms and findings were examined and quantitatively evaluated using a scoring system.RESULTSWe found 80 to 100% improvement rate in symptoms and findings for each infection. In addition, we found significant improvement in subjective evaluations from patient questionnaires even in the early stage of the treatment. X-ray examination for acute sinusitis demonstrated that the clinical efficacy was 84% (27/32) and 76% (19/25) patients were already improved within seven days. Among the detected 84 bacteria, 75 (89%) were identified as the major pathogenic bacteria of respiratory tract infections such as Streptococcus pneumoiae (27 strains) and Haemophillus influenzae (14 strains). Garenoxacin administration completely eradicated bacteria in 53 out of 54 cases (98%). There were 8 adverse events (8.3%) including 3 diarrhea cases (3.1%).CONCLUSIONThese results suggest that garenoxacin is a highly effective and safe antimicrobial agent in the treatment of community-acquired upper respiratory infections. Additionally, garenoxacin did not induce the growth of resistant bacteria because of its strong antimicrobial activity.